Equity Overview
Price & Market Data
Price: $1.74
Daily Change: +$0.0101 / 0.58%
Range: $1.72 - $1.80
Market Cap: $93,562,528
Volume: 771,822
Performance Metrics
1 Week: 1.16%
1 Month: 45.83%
3 Months: -5.91%
6 Months: -5.41%
1 Year: 18.24%
YTD: -25.85%
Company Details
Employees: 33
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.